Vor Biopharma Inc. Common Stock (VOR) Stock
NASDAQ · VOR
18.30
Fundamentals
Market cap
$1.10B
Price / Earnings ratio
1.7x
Price / Sales ratio
N/A
Price / Book ratio
-5.5x
Return on assets
-261.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
NeutralVORMay 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
VOR

Zacks Investment Research
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
NeutralVORApril 20, 2026
Zacks Investment ResearchNeutral
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
VOR

Zacks Investment Research
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
NeutralVORApril 2, 2026
Zacks Investment ResearchNeutral
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
VOR

Zacks Investment Research
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
NeutralVORApril 2, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
VOR
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy0
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
EPS forecast
Actual EPS
$-1.30
Q4FY25
$-1.45
Q1FY26
$-1.42
Q2FY26
The market is expecting earnings per share of -$1.42 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 8 articles
published over the past 14 days
Latest news

Zacks Investment Research
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
NeutralVORMay 7, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to Trade
VOR

Zacks Investment Research
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
NeutralVORApril 20, 2026
Zacks Investment ResearchNeutral
Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?
VOR

Zacks Investment Research
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
NeutralVORApril 2, 2026
Zacks Investment ResearchNeutral
Vor Biopharma (VOR) Upgraded to Buy: Here's Why
VOR

Zacks Investment Research
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
NeutralVORApril 2, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should Know
VOR

Stocktwits
VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage
NeutralVORDecember 9, 2025
StocktwitsNeutral
VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage
VOR

Stocktwits
Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch
NeutralVORDecember 9, 2025
StocktwitsNeutral
Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch
VOR

Zacks Investment Research
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
NeutralVORNovember 25, 2025
Zacks Investment ResearchNeutral
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know
VOR

InvestorPlace
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
NeutralVORMarch 28, 2024
InvestorPlaceNeutral
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
VOR
About Vor Biopharma Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees76
CEODr. Jean-Paul Kress M.D.
IPO DateFeb 5, 2021
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman, President & CEO | 1965 |
| Mr. Sandesh Mahatme L.L.M. | Chief Business Officer & CFO | 1965 |
| Dr. Robert Ang M.B.A., M.D., MBBS | Strategic Advisor | 1975 |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | 1971 |
| Ms. Adi Osovsky | General Counsel | — |
| Ms. Carol Lincoln CCP | Head of Human Resources | — |
| Mr. Dallan Murray | Chief Commercial Officer | 1970 |
| Dr. Navid Z. Khan Ph.D. | Chief Medical Affairs Officer | — |
| Dr. Jeremy Sokolove M.D. | Chief Medical Officer | 1974 |
Fundamentals
Valuation
Market cap$1.10B
Price-to-sales ratioN/A
Price-to-book value-5.45
Price-earnings ratio1.70
Return on Equity87.00%
Return on SalesN/A
Return on Assets-261.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$179.71
Income Statement
Average volume1,214,911
EBITDA$-876.54M
1 year high (52w)$49.95
1 year low (52w)$6.50
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
HOLD
0% Buy
100% Hold
0% Sell
Target price
$27.00
Est return
45.55%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.6 | +1.9 | -29.7 | +2.7 | ||||||||
| 2022 | -32.5 | +4.6 | -31.7 | -9.3 | -28.6 | +23.0 | -4.2 | +5.3 | -25.0 | +22.4 | -1.9 | +40.0 |
| 2023 | -22.0 | +5.5 | -2.4 | -14.9 | +9.6 | -34.8 | +2.0 | -21.1 | -20.6 | -6.4 | +11.8 | +17.2 |
| 2024 | +3.1 | -2.1 | +4.4 | -21.8 | -23.7 | -30.1 | -6.1 | -7.0 | -16.0 | +31.7 | +3.4 | +27.7 |
| 2025 | +26.8 | -19.4 | -24.6 | +9.5 | -69.7 | +590.8 | +44.8 | -6.2 | +19.4 | -38.6 | -62.8 | +70.3 |
| 2026 | +11.7 | +20.7 | +12.2 | -17.6 | +8.1 | +26.4 | +15.0 | +5.0 | -18.2 |



